Fundraising FoxBiotech Startups
11,136 companies tagged Biotech, with their investors and founders.
0 investors
Synthonics develops Metal Coordination Pharmaceuticals (MCPs), which chelate metal ions to known drugs to improve properties such as absorption, efficacy, and onset of action. The company holds four US patents for its MCP technologies and works in the pharmaceutical and biotech industry.
0 investors
Syntr Health Technologies makes the SyntrFuge System, an FDA-cleared device that automates the processing of autologous fat (microfat) for fat grafting, body contouring, and tissue healing. The device is aimed at clinical practices—including plastic, orthopedic, wound care, gastrointestinal, and veterinary surgeons—enabling in-office fat transfer procedures.
0 investors
Revr (SynVitro Bio) designs functional proteins by combining AI models with large-scale biophysical data generated from an automated wet lab platform, using a closed-loop process to speed up protein refinement. The company operates a cloud-based, API-accessible system that expresses and functionally tests roughly 1,000 proteins per week for protein engineering applications.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Talphera is a pharmaceutical company developing and commercializing therapies for medically supervised settings, with a lead candidate, Niyad (nafamostat mesylate), a regional anticoagulant for the extracorporeal circuit during renal replacement therapy. Its pipeline also includes nafamostat-based products for inflammatory and antiviral indications and ready-to-use prefilled syringes of ephedrine and phenylephrine for perioperative and acute-care use.
0 investors
0 investors
0 investors
0 investors
0 investors
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable. The drug, tested in the Phase 3 ORACAL trial, is a pharmaceutical treatment whose rights have been acquired by R-Pharm JSC.
0 investors
0 investors
TAXIS Pharmaceuticals is a biotech company developing novel anti-resistance agents targeting bacterial cell wall mechanisms to combat antimicrobial resistance across infectious diseases. The company serves healthcare providers, pharmaceutical partners, and patients affected by antibiotic-resistant infections.
0 investors
0 investors
0 investors
0 investors